• D-N-Acetylgalactosamine Product Overview

  2026-10-10

  D-N-Acetylgalactosamine (SKU B7904) is a cataloged small molecule described for conceptual glycoprotein and glycosylation research. No matched peer-reviewed paper evidence was available, so the product description does not establish validated performance or specific experimental applicability.

• LMO2–LDB1 Signaling in AML: Study Insights

  2026-10-09

  Lu et al. identify an LMO2/LDB1 protein complex as a functional contributor to acute myeloid leukemia (AML) cell survival and proliferation. By combining genetic perturbation, protein-interaction analysis, transcriptomics, and ChIP-seq, the study connects LDB1-dependent regulatory activity with apoptosis-related genes and shows that increased LMO2 can partially compensate for LDB1 loss.

• N6-Methyl-dATP and Translational Epigenetics

  2026-10-09

  N6-Methyl-dATP offers translational researchers a defined chemical lens for examining polymerase recognition, DNA replication fidelity, methylation-linked mechanisms, and genomic stability—while recent AML findings provide an important biological context rather than direct validation of the nucleotide probe.

• Five Questions on Plasmid DNA and AML Evidence

  2026-10-08

  A source-grounded overview separating plasmid DNA purification principles from the evidence linking LMO2–LDB1 biology to acute myeloid leukemia, with attention to study design, interpretation, scope and limitations.

• Pol II Degradation and Transcription-Independent Death

  2026-10-08

  A January 2025 bioRxiv preprint proposes that RNA polymerase II degradation can activate cell death through a mechanism not reducible to transcriptional loss. The distinction is important for interpreting transcription-targeting compounds, including HDAC inhibitors, but the finding remains provisional because the study is a non-peer-reviewed preprint and the supplied record does not provide complete methods or outcome statistics.

• Dinaciclib–VHL Synthetic Lethality in Renal Cancer

  2026-10-07

  Nelson and colleagues report that the CDK inhibitor Dinaciclib preferentially suppresses VHL-deficient clear cell renal cell carcinoma (CC-RCC) in cellular and orthotopic patient-derived xenograft models. The findings connect VHL loss with a potentially exploitable cell-cycle and survival dependency, while remaining preclinical and requiring clinical validation.

• PPT and the Next Era of ERα Translational Research

  2026-10-07

  PPT offers a receptor-selective lens for testing how ERα biology intersects with FOXM1, ceRNA regulation, and immune hypotheses in female lung adenocarcinoma. This article connects supplier-reported pharmacology with a 2023 preprint, while distinguishing mechanistic opportunity from clinical evidence.

• (-)-Blebbistatin: Evidence, Scope and Limits

  2026-10-06

  A source-grounded overview of (-)-Blebbistatin, covering its proposed non-muscle myosin II mechanism, evidence quality, interpretation in cardiac research, and key limitations.

• Cimetidine in Cancer and BBB Research Context

  2026-10-06

  This overview places Cimetidine in the context of histamine-2 receptor pharmacology, cancer research, and contemporary blood-brain barrier modeling. It separates supplier descriptions and mechanistic hypotheses from findings reported in a 2025 surrogate BBB study, while outlining evidence strength, translational relevance, and key limits on applying that model to Cimetidine specifically.

• Hsa_circ_0001944, FXR/TLR4, and Ferroptosis

  2026-10-05

  A 2025 Toxics study links reduced hsa_circ_0001944 with altered FXR/TLR4 signaling, ferroptosis-related markers, and collagen formation in NiONP-exposed LX-2 cells. Its findings position the circRNA–FXR axis as a mechanistic hypothesis for toxicant-associated hepatic stellate-cell activation, while remaining limited by its cell-model design and marker-based evidence.

• BMS-345541 in NF-κB and Angiogenesis Research

  2026-10-05

  BMS-345541 is a selective IKK-1/IKK-2 inhibitor used as a pharmacological tool for studying NF-κB signaling. This overview examines its research context through a 2020 study of thymosin-β4, Notch/NF-κB signaling, and angiogenesis in critical limb ischemia models. It distinguishes supplier-reported properties from findings in the primary literature, evaluates the strength of pathway-based evidence, and outlines limitations affecting interpretation in inflammation research, vascular biology, and cancer research.

• Coelenterazine: From ROS Signal to Translation

  2026-10-04

  Coelenterazine can connect luciferase-compatible reporting with chemiluminescent detection of selected reactive oxygen species, but translational value depends on separating substrate chemistry from biological interpretation. This thought-leadership article links that challenge to Greenwood and colleagues’ brain–kidney study of liraglutide, highlighting how multisystem validation can make oxidative stress measurement more credible.

• THBS1 in Laryngeal Cancer: Evidence and Implications

  2026-10-03

  The reference study combines transcriptomic datasets, machine-learning feature selection, survival analysis, pathway evaluation, and cell-based assays to identify THBS1 as a prognostic biomarker and possible therapeutic vulnerability in laryngeal cancer. Its findings connect high THBS1 expression with tumor-associated biology and an immune-suppressive transcriptomic context, while also highlighting the need for prospective clinical validation and more direct mechanistic studies.

• NF-κB/miR-202-5p/HMGB2 in Septic AKI

  2026-10-02

  The reference study identifies an adaptive NF-κB/miR-202-5p/HMGB2 feedback loop that limits renal inflammation and tubular injury during sepsis-associated acute kidney injury. Its combination of in vivo and LPS-stimulated tubular-cell models with ChIP, luciferase, miRNA, and siRNA experiments provides a mechanistic framework for interpreting NF-κB-dependent cytokine regulation in septic AKI.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-10-01

  BRD4770 is a G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence and cancer-cell growth phenotypes. This workflow translates its reported PANC-1 activity and the c-MYC/G9a research framework into practical dosing, readout, and troubleshooting strategies.

8485 records 1/566 page Next 12345 下5页 Last page